Alcoholic hepatitis
Drug research and approvals for alcoholic hepatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 28 studies of alcoholic hepatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 28
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07631637 · Phase 2 · Regeneron Pharmaceuticals · starts Jul 6, 2026
- Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)NCT07428538 · Phase 3 · Bausch Health Americas, Inc. · starts Jan 29, 2026
- Integrative Epidemiology of Prognosis in Patients With Acute Alcoholic Hepatitis at AP-HPNCT07262515 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jul 19, 2024
- Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver DiseaseNCT07060547 · Not reported · HepQuant, LLC · starts Jun 10, 2025
- PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic HepatitisNCT06956482 · Phase 3 · University Hospital, Lille · starts May 22, 2026
- A-TANGO Phase 2 StudyNCT06890039 · Phase 2 · Yaqrit Ltd · starts Jun 29, 2026
- Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.NCT06843148 · Not applicable · Université de Sherbrooke · starts Jun 22, 2026
- LivQ-box® Parameters in the Diagnosis of Liver InflammationNCT06802731 · Not reported · Wuxi Hisky Medical Technology Co Ltd · starts Jan 1, 2024
- Recompensation in Alcohol Related HepatitisNCT06740318 · Not applicable · Nina Kimer · starts Nov 25, 2024
Phase 3 5
- PentoxifyllineAdenosine A2 receptor antagonist
- RifaximinBacterial DNA-directed RNA polymerase inhibitor
- AcetylcysteineGlutathione precursor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- AmoxicillinBacterial penicillin-binding protein inhibitor
Phase 2 12
- Larsucosterol
- AnakinraInterleukin-1 receptor antagonist
- PrednisoneGlucocorticoid receptor agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Obeticholic acidBile acid receptor FXR agonist
- CanakinumabInterleukin-1 beta inhibitor
- RilonaceptInterleukin-1 beta inhibitor
- SelonsertibMitogen-activated protein kinase kinase kinase 5 inhibitor
- EmricasanCaspase inhibitor
- PyridoxineSupplement
- Zinc sulfate
- Zinc ion
Phase 1 or earlier 2
- Eflepedocokin alfaIL22 Receptor agonist
- CiprofloxacinBacterial DNA gyrase inhibitor
How its trials ended
102 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 24 whose ending is known, 13% met their primary endpoint, 29% missed it and 58% stopped early.
- Completed, result not reported3635%
- Ongoing2323%
- Status unknown1919%
- Missed its primary endpoint77%
- Stopped: other or unclear55%
- Met its primary endpoint33%
- Stopped: lack of efficacy33%
- Stopped: safety22%
- Stopped: funding22%
- Stopped: enrollment or feasibility11%
- Stopped: sponsor or business decision11%
| Feb 27, 2024 | A phase 1b multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of SZN-043, in participants with severe alcohol-associated…SZN-043 | Surrozen Operating, Inc. | Closed |
| Sep 8, 2016 | A phase 2, double-blind, randomized study evaluating the safety, tolerability, and efficacy of GS-4997 in combination with prednisolone versus prednisolone…GS-4997 | Gilead Sciences | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Mar 18, 1994 | OxandroloneTreatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition. | Bio-Technology General Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA